Sort
82,697 grants matching “vaccine development”
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2017 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2020 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2016 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2021 · CA
Immuno-Targeted Therapy for Melanoma
$899,241Antoni Ribas · University Of California Los Angeles · R35 · FY2018 · CA
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
$899,151Jason B Harris · Massachusetts General Hospital · R01 · FY2014 · AI
NLM's Personal Health Record and Consumer Service R&D
$899,125Clement McDonald · National Library Of Medicine · ZIA · FY2014 · LM
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses
$899,116Emmett Vance Schmidt · Massachusetts General Hospital · U01 · FY2007 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop
$899,104Susan B Zolla-Pazner · New York University School Of Medicine · P01 · FY2015 · AI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants
$899,083Kristina Abel · Univ Of North Carolina Chapel Hill · R01 · FY2019 · DE
MICROCHIP DRUG DELIVERY SYSTEM
$899,016Massachusetts Institute Of Technology · R24 · FY2001 · AI
Humoral Responses
$898,908Guido Ferrari · Wistar Institute · U19 · FY2017 · AI
Mechanisms of Protection of Universal Therapeutic Antibodies to Influenza A
$898,865Silke Paust · Scripps Research Institute, The · R01 · FY2019 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$898,846Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Disease Modeling of Influenza and Other Emerging Respiratory Viral Pathogens
$898,846Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
$898,658Judith A Woodfolk · University Of Virginia · U01 · FY2016 · AI
Building 41 Flow Cytometry Core
$898,346Katherine McKinnon · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA
Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection
$898,325Chad Roy · Tulane University Of Louisiana · N01 · FY2021 · AI
O-polysaccharide (OPS)-IpaB Conjugate Vaccine to Prevent Shigellosis
$898,263Marcela F Pasetti · University Of Maryland Baltimore · R01 · FY2023 · AI
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses
$898,140Emmett Vance Schmidt · Massachusetts General Hospital · U01 · FY2008 · AI
THE TEDDY STUDY - COLORADO CLINICAL CENTER
$898,124Marian J. Rewers · University Of Colorado Denver · U01 · FY2010 · DK
The Danger Model 2: how tissues control Immunity
$897,990Polly C Matzinger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Evaluation of a new class of antimicrobial agents against Clostridium difficile
$897,906Saul R Tzipori · Tufts University Boston · R56 · FY2011 · AI
Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis
$897,854Shabaana A. Khader · University Of Chicago · R01 · FY2023 · AI
NONHUMAN PRIMATE PURCHASE AND HOLDING
$897,758Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2018 · AI